CMV-associated Immunomodulation in Renal Transplant Patients
NCT ID: NCT06976008
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
60 participants
INTERVENTIONAL
2025-10-01
2029-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.
NCT02064699
A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
NCT02067169
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
NCT06263218
Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients
NCT01558037
Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients
NCT00436384
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Kidney transplant recipients followed since the day of the transplantation
Kidney transplant recipients followed since the day of the transplantation
blood sampling
Blood samples will be taken at different timepoints following CMV viremia to evaluate the impact of CMV viremia over time.
kidney transplant recipients with CMV viremia
kidney transplant recipients with CMV viremia
blood sampling
Blood samples will be taken at different timepoints following CMV viremia to evaluate the impact of CMV viremia over time.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sampling
Blood samples will be taken at different timepoints following CMV viremia to evaluate the impact of CMV viremia over time.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* patients with end-stage renal failure programmed for kidney transplantation with a live donor
2. nd cohort :
* Age \> 18 years
* kidney transplant recipient with CMV viremia
Exclusion Criteria
For patients with end-stage renal failure scheduled to receive a kidney transplant from a living donor :
* Patients with an active viral (other than CMV), bacterial or fungal infection at the time of inclusion
* patients receiving a desensitization protocol (ABO or anti-HLA)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
URC-CIC Paris Descartes Necker Cochin
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexandra Serris
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Bicêtre
Le Kremlin-Bicêtre, , France
Hôpital européen Georges Pompidou
Paris, , France
Hôpital Necker-Enfants Malades
Paris, , France
Insitut Pasteur
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Serris
Role: backup
Serris
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID-RCB Number : 2024-A01039-38
Identifier Type: OTHER
Identifier Source: secondary_id
APHP240837
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.